arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


Examining the Evidence:

The Latest Data for Optimal Management of Diabetic Macular Edema

Presented by the Johns Hopkins University School of Medicine.

Supported by an educational grant from Alimera Sciences.


OVERVIEW
Treatment of patients with diabetic macular edema (DME) is multifaceted, involving the management of metabolic parameters and direct ocular treatment, among many others. Consideration of patients’ intraocular pressure, genetic background, and the intended length of treatment should all be given prior to and during the course of therapy. As of late, the availability of intravitreal treatments, including antivascular endothelial growth factor (anti-VEGF) and corticosteroid delivery systems have shifted treatment goals from the previous standard of care. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges resulting from recent clinical trials of these therapies, to evaluate the efficacy and safety of customized treatment plans, and to develop customized treatment courses via interactive case scenarios.

GOAL
The goal of this activity is to provide retina specialists with the most up-to-date clinical knowledge and strategies for the optimal treatment and management of patients with DME.

INTENDED AUDIENCE
This activity is designed for retina specialists. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • COMPARE the efficacy and safety of available treatments for DME.
  • COMPARE the efficacy and safety of available treatments for DME.
  • DISCUSS the rates of ocular hypertension for all available treatments for DME.
  • RECOGNIZE patient populations with unmet needs from anti-VEGF treatment of DME.
  • IDENTIFY patients who would most benefit from the use of alternatives to anti-VEGF treatment of DME.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CHAIRPERSON
Peter A. Campochiaro, MD
George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience
Professor of Ophthalmology
Johns Hopkins Wilmer Eye Institute
Baltimore, Maryland

FACULTY
Pravin U. Dugel, MD
Managing Partner
Retinal Consultants of Arizona LTD
Retinal Research Institute LLC
Phoenix, Arizona

Clinical Professor
USC Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, California

Alexander M. Eaton, MD
Founder and Medical Director
Retina Health Center, PL
Fort Myers, Florida

Richard K. Parrish II, MD
Edward W. D. Norton, MD Chair in Ophthalmology
Professor
Associate Dean for Graduate Medical Education
Director – Glaucoma Service
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Designated Institutional Official - Jackson Health System/Jackson
Memorial Hospital
Miami, Florida

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this activity: 60 minutes.

Release date: September 30, 2015.   Expiration date: September 30, 2017.

DISCLOSURE POLICIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Participating Faculty Disclosures
Peter A. Campochiaro, MD, reports receiving grants/research support from AbbVie Inc, Allergan, Inc, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, Oxford BioMedica, Regeneron Pharmaceuticals, Inc, and Roche; serving as a consultant for Advanced Cell Technology, Aerpio Therapeutics, Alimera Sciences, Allegro Ophthalmics LLC, AsclepiX Therapeutics LLC, Akebia Therapeutics, AGTC, Eleven Biotherapeutics, Genentech Inc, Kala Pharmaceuticals Inc, Interxon, Regeneron Pharmaceuticals Inc, and RXi Pharmaceuticals; and reports receiving equity/royalties from GrayBug Inc.

Alexander Eaton, MD, reports receiving grants/research support from Allergan Inc, Genentech Inc, and Regeneron Pharmaceuticals Inc; and serving as a consultant for and having ownership interest in Alimera Sciences.

No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Planner Disclosures
Peter A. Campochiaro, MD, reports receiving grants/research support from AbbVie Inc, Allergan, Inc, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, Oxford BioMedica, Regeneron Pharmaceuticals, Inc, and Roche; serving as a consultant for Advanced Cell Technology, Aerpio Therapeutics, Alimera Sciences, Allegro Ophthalmics LLC, AsclepiX Therapeutics LLC, Akebia Therapeutics, AGTC, Genentech Inc, Kala Pharmaceuticals Inc, Interxon, Regeneron Pharmaceuticals Inc, and RXi Pharmaceuticals; and reports receiving equity/royalties from GrayBug Inc.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

FEE INFORMATION
There is no fee for this educational activity.

OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
Dr Campochiaro—bevacizumab.
Dr Eaton—bevacizumab and triamcinolone.

All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANTS

I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu. For CME Certificates, please call 410-502-9634.

Johns Hopkins University School of Medicine Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland
21205-2195
Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
(Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY
Instructions

Please complete the pre-assessment, listen to the following presentation, and complete the post-assessment and evaluation to receive CME credit for this activity. A certificate of participation will be available online immediately following successful completion of the activity.

Pre-assessment

Is Suppression of VEGF Sufficient for Management of DME?
Pravin U. Dugel, MD

Steroid-Induced Increase in Intraocular Pressure: How Big a Problem Is It?
Richard K. Parrish II, MD

Challenging Case Scenarios: Who Are the Best Candidates for Various Treatment Options?
Alexander M. Eaton, MD

Post-assessment

This activity was developed in collaboration with ASiM.


The information you enter here will be used to generate your CME certificate.
Please complete all fields to ensure accurate registration.
procced to pretest
footer